PVI
MYGN icon

Pura Vida Investments’s Myriad Genetics MYGN Stock Holding History

Pura Vida Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,725
Closed -$954K – 63
2024
Q1 		$954K Sell
44,725
-5,275
-11% -$113K 0.16% 47
2023
Q4 		$957K Buy
+50,000
New +$865K 0.15% 46

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pura Vida Investments's MYGN Position: Q2 2024 in Review

Pura Vida Investments sold out of Myriad Genetics (MYGN) in Q2 2024, closing a stake of 44,725 shares — an estimated $954K sold.

Pura Vida Investments first reported a position in MYGN in Q4 2023 and held it in 2 quarters. The position peaked at $957K in Q4 2023. 223 funds tracked by Wall St. Rank hold MYGN as of Q2 2024.

  • Pura Vida Investments reported no remaining Myriad Genetics position as of Q2 2024 after selling out during the quarter.
  • Pura Vida Investments sold 44,725 Myriad Genetics shares in Q2 2024, an estimated $954K.
  • Pura Vida Investments first reported a position in Myriad Genetics in Q4 2023 and held it in 2 quarters.
  • Pura Vida Investments's Myriad Genetics position peaked at $957K in Q4 2023.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2024.

Based on Pura Vida Investments's 13F filing for Q2 2024, filed 14 Aug 2024.